Gainers
-
Eleven Biotherapeutics Inc (NASDAQ: EBIO) shares
rose 42.9 percent to $2.80 in pre-market trading after the company reported the effectiveness of IND application for EBI-031.
-
Mitel Networks Corporation (NASDAQ: MITL) rose
22.1 percent to $7.35 in pre-market trading as Polycom reported an end of Mitel merger deal.
-
Barracuda Networks Inc (NYSE: CUDA) shares rose
15.7 percent to $17.94 in pre-market trading as the company reported stronger-than-expected results for its first quarter. The
company reported that CFO David Faugno will be stepping down and current chief accounting officer, Dustin Driggs, will replace
Faugno.
-
Polycom Inc (NASDAQ: PLCM) shares rose 13.6
percent to $12.35 in pre-market trading after the company revealed Friday that private equity firm, Siris Capital Group, LLC
and its affiliates, have submitted a unilaterally binding offer to buy all outstanding shares for $12.50 per share in cash.
-
Smith & Wesson Holding Corp (NASDAQ: SWHC) shares
rose 5 percent to $29.70 in pre-market trading. Gun manufacturers shares rose after a deadly shooting in downtown Dallas. Three
people were in custody while a fourth suspect exchanged gunfire with police authorities. A sniper fatally shot 11 officers,
five fatally.
-
Gap Inc (NYSE: GPS) rose 3.6 percent to $22.40 in
pre-market trading. Gap reported a 2 percent rise in its comparable sales for June, while total sales increased to $1.57
billion from $1.54 billion.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Losers
-
Juno Therapeutics Inc (NASDAQ: JUNO) shares fell
26.2 percent to $30.12 in pre-market trading after the company announced JCAR015's Phase 2 trial was put on hold after two
patients died last week.
-
Kite Pharma Inc (NASDAQ: KITE) shares dipped 7.9
percent to $48.00 in pre-market trading after Juno Therapeutics reported an FDA clinical hold on JCAR015's Phase 2 trial.
-
WD-40 Company (NASDAQ: WDFC) shares tumbled 4.2
percent to $111.10 in the pre-market trading session. WD-40 reported upbeat earnings for its third quarter on Thursday.
However, the company posted weaker-than-expected sales and lowered its revenue outlook for the year.
-
Galena Biopharma Inc (NASDAQ: GALE) fell 2.6
percent to $0.501 in pre-market trading. Galena Biopharma priced 28 million shares at $0.45 per share.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.